Mark Yarchoan

17.2k total citations · 10 hit papers
151 papers, 8.1k citations indexed

About

Mark Yarchoan is a scholar working on Oncology, Immunology and Hepatology. According to data from OpenAlex, Mark Yarchoan has authored 151 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 35 papers in Immunology and 35 papers in Hepatology. Recurrent topics in Mark Yarchoan's work include Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (33 papers) and Immunotherapy and Immune Responses (26 papers). Mark Yarchoan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (33 papers) and Immunotherapy and Immune Responses (26 papers). Mark Yarchoan collaborates with scholars based in United States, Spain and New Zealand. Mark Yarchoan's co-authors include Elizabeth M. Jaffee, Daniel A. Laheru, Solange Peters, Timothy A. Chan, Sergio A. Quezada, Albrecht Stenzinger, Charles Swanton, Burles A. Johnson, Eric R. Lutz and Steven E. Arnold and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Mark Yarchoan

135 papers receiving 8.0k citations

Hit Papers

Development of tumor mutation burden as an immunotherapy ... 2017 2026 2020 2023 2018 2023 2017 2019 2024 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    2018 1.8k citations Mark Yarchoan, Elizabeth M. Jaffee et al. profile →
  2. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
    2023 740 citations Amit G. Singal, Josep M. Llovet et al. Hepatology profile →
  3. Targeting neoantigens to augment antitumour immunity
    2017 727 citations Mark Yarchoan, Daniel A. Laheru et al. profile →
  4. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    2019 386 citations Mark Yarchoan, Lee A. Albacker et al. JCI Insight profile →
  5. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
    2024 162 citations Josep M. Llovet, Roser Pinyol et al. Nature Reviews Clinical Oncology profile →
  6. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
    2023 153 citations Suzanne L. Topalian, Patrick M. Forde et al. profile →
  7. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
    2024 111 citations Mark Yarchoan, Thomas U. Marron et al. profile →
  8. Biomarkers for immunotherapy of hepatocellular carcinoma
    2023 109 citations Mark Yarchoan et al. Nature Reviews Clinical Oncology profile →
  9. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
    2023 72 citations Mark Yarchoan, Richard S. Finn et al. profile →
  10. Recent advances in therapeutic cancer vaccines
    2025 19 citations Neeha Zaidi, Elizabeth M. Jaffee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Yarchoan United States 39 4.3k 2.2k 2.1k 2.0k 1.5k 151 8.1k
E. Gabriela Chiorean United States 42 4.7k 1.1× 1.7k 0.8× 1.5k 0.7× 2.1k 1.1× 1.7k 1.1× 209 7.1k
Aung Naing United States 58 5.8k 1.3× 2.1k 1.0× 3.0k 1.4× 4.4k 2.2× 3.0k 2.0× 483 12.5k
Moritz Koch Germany 46 4.6k 1.1× 1.2k 0.6× 1.5k 0.7× 2.2k 1.1× 2.1k 1.4× 98 7.8k
Ronit Simantov United States 36 3.3k 0.8× 1.4k 0.7× 4.3k 2.1× 5.5k 2.8× 2.6k 1.7× 88 11.2k
Peter Birner Austria 49 4.0k 0.9× 1.2k 0.6× 2.1k 1.0× 3.3k 1.7× 2.2k 1.4× 169 9.0k
Massimo Roncalli Italy 59 4.7k 1.1× 1.6k 0.7× 3.3k 1.6× 3.2k 1.6× 1.8k 1.2× 228 11.5k
Jung Ho Kim South Korea 39 3.4k 0.8× 1.1k 0.5× 1.1k 0.5× 1.7k 0.9× 665 0.4× 151 6.7k
Tae‐You Kim South Korea 48 4.3k 1.0× 575 0.3× 2.5k 1.2× 2.0k 1.0× 1.5k 1.0× 189 7.6k
Shuang–Jian Qiu China 48 3.6k 0.8× 990 0.5× 1.2k 0.6× 2.7k 1.4× 2.0k 1.3× 174 8.6k
Wells A. Messersmith United States 52 5.3k 1.2× 1.1k 0.5× 1.8k 0.9× 4.3k 2.2× 1.7k 1.1× 298 9.5k

Countries citing papers authored by Mark Yarchoan

Since Specialization
Citations

This map shows the geographic impact of Mark Yarchoan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yarchoan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yarchoan more than expected).

Fields of papers citing papers by Mark Yarchoan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Yarchoan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yarchoan. The network helps show where Mark Yarchoan may publish in the future.

Co-authorship network of co-authors of Mark Yarchoan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Yarchoan. A scholar is included among the top collaborators of Mark Yarchoan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Yarchoan. Mark Yarchoan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yarchoan, Mark, et al.. (2026). Anatomic subsets of cholangiocarcinoma: More different than alike. Hepatology.
2.
Long, Donald, Marina Chan, K. Rosanna, et al.. (2024). Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma. Cell Reports Medicine. 5(9). 101699–101699. 1 indexed citations
3.
Llovet, Josep M., Roser Pinyol, Mark Yarchoan, et al.. (2024). Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature Reviews Clinical Oncology. 21(4). 294–311. 162 indexed citations breakdown →
4.
Heumann, Thatcher, Mark Yarchoan, Jiayun Lu, et al.. (2024). A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4017–4017. 3 indexed citations
5.
Kessler, Michael D., Xiaoshan M. Shao, Archana Balan, et al.. (2024). SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors. Cancer Research Communications. 4(12). 3137–3150. 2 indexed citations
6.
McMiller, Tracee L., Sepideh Besharati, Mark Yarchoan, et al.. (2024). Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy. Journal for ImmunoTherapy of Cancer. 12(11). e010201–e010201. 3 indexed citations
7.
Deshpande, Atul, Hanwen Wang, Haoyang Mi, et al.. (2024). Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer Research. 84(16). 2734–2748. 13 indexed citations
8.
Huff, Amanda L., Jacob T. Mitchell, Emily F. Davis-Marcisak, et al.. (2023). CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight. 8(23). 14 indexed citations
9.
Yarchoan, Mark, Subir Goyal, Yuan Liu, et al.. (2022). Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research. 28(19). 4336–4345. 10 indexed citations
10.
Lalazar, Gadi, Guangrong Zheng, Peiyi Zhang, et al.. (2022). Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight. 7(17). 18 indexed citations
11.
Sové, Richard J., et al.. (2022). Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. Journal for ImmunoTherapy of Cancer. 10(11). e005414–e005414. 32 indexed citations
12.
Chen, Krista Y., Aleksandra Popović, David Hsiehchen, et al.. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers. 14(21). 5347–5347. 13 indexed citations
13.
Dennison, Lauren, Aditya Mohan, James M. Leatherman, et al.. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. 9(10). 1187–1201. 17 indexed citations
14.
Osipov, Arsen, Su Jin Lim, Aleksandra Popović, et al.. (2020). Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clinical Cancer Research. 26(18). 4842–4851. 69 indexed citations
15.
Danilova, Ludmila, Won Jin Ho, Qingfeng Zhu, et al.. (2019). Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research. 7(6). 886–895. 180 indexed citations
16.
Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations
17.
Kim, Amy K., Faiz Gani, Andrew J. Layman, et al.. (2019). Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research. 7(5). 805–812. 20 indexed citations
18.
Yarchoan, Mark, Lee A. Albacker, Alexander C. Hopkins, et al.. (2019). PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 4(6). 386 indexed citations breakdown →
19.
Yarchoan, Mark, Chiung‐Yu Huang, Qingfeng Zhu, et al.. (2019). A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Medicine. 9(4). 1485–1494. 68 indexed citations
20.
Leaf, Rebecca Karp, Deepa Rangachari, James W. Mier, et al.. (2019). Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology. 94(5). 563–574. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Aung Naing Breakdown of academic impact, for papers by Moritz Koch Breakdown of academic impact, for papers by Ronit Simantov Breakdown of academic impact, for papers by Peter Birner Breakdown of academic impact, for papers by Massimo Roncalli Breakdown of academic impact, for papers by Jung Ho Kim Breakdown of academic impact, for papers by Tae‐You Kim Breakdown of academic impact, for papers by Shuang–Jian Qiu Breakdown of academic impact, for papers by Wells A. Messersmith
Rankless by CCL
2026